Estrella Immunopharma Inc.
ESLA | NASDAQ
$0.52
-$0.01 (-1.70%)
Sep 21, 2026, 11:09 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Jun 29, 2024 | FY 2022 Dec 30, 2022 | FY 2021 Jun 29, 2022 | FY 2020 Jun 29, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -13.06M | -8.85M | -7.31M | -1.57M | -1.69M | -733.69K |
Interest Income | n/a | n/a | n/a | 654.07K | 1.43K | n/a |
Pretax Income | -13.06M | -8.85M | -7.31M | -915.46K | -1.69M | -733.69K |
Net Income | -13.06M | -8.85M | -7.31M | -996.1K | -1.69M | -733.69K |
Selling & General & Admin | 2.81M | 2.44M | 3.2M | 663.19K | 296.25K | 276.46K |
Research & Development | 10.25M | 6.41M | 4.11M | 10.45M | 1.39M | 457.23K |
Other Expenses | n/a | n/a | n/a | -9.54M | n/a | n/a |
Operating Expenses | 13.06M | 8.85M | 7.31M | 1.57M | 1.69M | 733.69K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 13.06M | 8.85M | 7.31M | 1.57M | 1.69M | 733.69K |
Income Tax Expense | 838 | 1.69K | 1.63K | 80.65K | n/a | n/a |
Shares Outstanding (Basic) | 36.82M | 36.68M | 35.2M | 5.76M | 5.85M | 35.2M |
Shares Outstanding (Diluted) | 36.82M | 36.68M | 35.2M | 5.76M | 5.85M | 35.2M |
EPS (Basic) | -0.35 | -0.24 | -0.21 | -0.17 | -0.04 | -0.02 |
EPS (Diluted) | -0.35 | -0.24 | -0.21 | -0.17 | -0.04 | -0.02 |
EBITDA | -13.06M | -8.85M | -7.31M | -686.97K | -11.16K | -733.69K |
EBIT | -13.06M | -8.85M | -7.31M | -915.46K | -247.72K | -733.69K |
Depreciation & Amortization | n/a | n/a | n/a | 228.49K | 236.56K | n/a |
Add to Watchlist
Select watchlists to add or remove ESLA